Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.92 -0.6%	$11.15	$3.98 ▼ $13.37	$1.98B	1.92	2.10 million shs	1.37 million shs
ANIP ANI Pharmaceuticals	$90.00 +1.4%	$67.34	$52.50 ▼ $90.23	$1.92B	0.61	623,678 shs	604,501 shs
MESO Mesoblast	$15.86 +4.4%	$12.96	$6.00 ▼ $22.00	$1.94B	2.4	287,053 shs	286,741 shs
PRME Prime Medicine	$3.64 -4.5%	$3.28	$1.11 ▼ $5.17	$489.85M	2.39	2.51 million shs	2.37 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-0.62%	+3.03%	+16.82%	+42.76%	+193.64%
ANIP ANI Pharmaceuticals	+1.42%	+30.42%	+40.63%	+50.03%	+52.03%
MESO Mesoblast	+4.41%	+3.73%	+44.71%	+35.32%	+145.13%
PRME Prime Medicine	-4.46%	-1.09%	-15.15%	+128.93%	-11.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.8015 of 5 stars	1.4	1.0	4.2	2.7	2.5	0.6
ANIP ANI Pharmaceuticals	3.3934 of 5 stars	1.5	1.0	3.3	3.8	3.3	1.3
MESO Mesoblast	2.4409 of 5 stars	2.6	4.0	0.0	3.9	0.8	0.6
PRME Prime Medicine	3.6895 of 5 stars	4.4	1.0	0.0	2.3	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.22% Downside
ANIP ANI Pharmaceuticals	3.00	Buy	$84.75	-5.83% Downside
MESO Mesoblast	3.20	Buy	$18.00	13.49% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	144.96% Upside

Current Analyst Ratings Breakdown

Latest PRME, MESO, ADPT, and ANIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$65.00 ➝ $77.00
8/8/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $93.00
8/8/2025	ANIP ANI Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$94.00
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/5/2025	MESO Mesoblast	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
7/10/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$84.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.99	N/A	N/A	$1.18 per share	10.95
ANIP ANI Pharmaceuticals	$614.38M	3.17	$7.71 per share	11.68	$20.16 per share	4.46
MESO Mesoblast	$5.90M	344.08	N/A	N/A	$4.21 per share	3.77
PRME Prime Medicine	$4.96M	98.74	N/A	N/A	$1.37 per share	2.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	N/A
ANIP ANI Pharmaceuticals	-$18.52M	-$0.77	N/A	21.38	N/A	-1.37%	25.03%	8.00%	N/A
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/27/2025 (Estimated)
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Latest PRME, MESO, ADPT, and ANIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	H2 2025	MESO Mesoblast	-$0.20	N/A	N/A	N/A	$7.48 million	N/A
8/8/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.42	$1.80	+$0.38	$0.36	$187.18 million	$211.37 million
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	39.73%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
ANIP ANI Pharmaceuticals	1.39	2.54	1.96
MESO Mesoblast	0.22	0.96	0.63
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ANIP ANI Pharmaceuticals	76.05%
MESO Mesoblast	1.43%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ANIP ANI Pharmaceuticals	11.10%
MESO Mesoblast	18.80%
PRME Prime Medicine	22.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
MESO Mesoblast	80	128.00 million	103.93 million	Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable

PRME, MESO, ADPT, and ANIP Headlines

Recent News About These Companies

Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00

August 10, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Price Target Cut to $10.00 by Analysts at Chardan Capital

August 10, 2025 | americanbankingnews.com

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

August 8, 2025 | tipranks.com

PRME Revenue Misses by 73%

August 8, 2025 | aol.comA

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What Happened

August 6, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying Activity

August 6, 2025 | americanbankingnews.com

Prime Medicine Holds Special Stockholder Meeting

August 5, 2025 | tipranks.com

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity

August 5, 2025 | marketbeat.com

Friday’s Insider Trades: Key Buys and Sells in US Stocks Revealed

August 4, 2025 | investing.com

Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) Stock

August 2, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares

August 2, 2025 | insidertrades.com

Prime Medicine Halts Sales Agreement Prospectus

August 1, 2025 | theglobeandmail.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

August 1, 2025 | finance.yahoo.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

August 1, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Shares Gap Down - Here's Why

August 1, 2025 | marketbeat.com

Prime Medicine stock falls after pricing public offering

August 1, 2025 | za.investing.com

JonesTrading Maintains a Buy on Prime Medicine (PRME)

August 1, 2025 | msn.com

Prime Medicine (NYSE:PRME) Trading Up 6.9% - Here's Why

July 31, 2025 | marketbeat.com

Prime Medicine Announces Pricing of Public Offering

July 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, MESO, ADPT, and ANIP Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.92 -0.08 (-0.62%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$13.02 +0.10 (+0.74%)

As of 08:06 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ANI Pharmaceuticals NASDAQ:ANIP

$90.00 +1.26 (+1.42%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$91.70 +1.71 (+1.89%)

As of 08:00 AM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Mesoblast NASDAQ:MESO

$15.86 +0.67 (+4.41%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$16.26 +0.40 (+2.52%)

As of 08:10 AM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Prime Medicine NYSE:PRME

$3.64 -0.17 (-4.46%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.01 (+0.41%)

As of 08:04 AM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time